0JDI.L Reddit Mentions

Track 0JDI.L's AI-powered predictions, market trends, and investment insights.

0JDI.L AI Prediction 0JDI.L Sentiment 0JDI.L StockTwits

Mock Tradesimulated, no real money

You don't hold 0JDI.L in your mock portfolio yet.

0JDI.L Reddit Mentions

Track 0JDI.L's AI-powered predictions, market trends, and investment insights.

0JDI.L AI Prediction 0JDI.L Sentiment 0JDI.L StockTwits

Evidence Stack

What Changed?

Key moves vs recent baseline (last day / last week)

Price (1d)-1.4%

Price (7d)-1.5%

Volume vs avg+4.2x

Reddit mentions vs 7D+0%

Volatility vs normal1.0x

Why Now?

Plain-English summary of the biggest drivers (informational)

Risk Flags

Potential risk factors to review

Low liquidity

Avg volume 1K — may be hard to exit

Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.

Invalidation Signals

Reassess your thesis if any of these occur:

Price breaks below ~$73.08 (recent support level)

Upgrade to see the full Evidence Stack

What Changed, Why Now, and Risk Flags — available on the Investor plan and above

Get Started

0JDI.L AI Stock Analysis

Financial Performance

bearish

Ionis remains unprofitable, with a negative EPS and a meaningless, highly negative P/E ratio reflecting losses rather than earnings power. While the small per‑share loss (-0.03) suggests losses are not massive on a per‑share basis, the business is still not generating positive net income or sustainable profitability. Overall, current fundamentals lean unfavorably from a pure earnings and valuation standpoint.

Negative EPS of -0.03 indicates the company is still loss‑making, which is typical for development‑stage or R&D‑heavy biopharma but remains a financial risk.
The extremely negative P/E ratio (-2919.64) is not a sign of high growth but rather a function of very low or negative earnings, making traditional valuation metrics less useful.
Absent clear evidence of sustained revenue growth or improving margins in the data provided, the financial picture skews toward speculative, pipeline‑driven value rather than earnings‑driven value.

Stock Price & Technicals

bullish

The stock trades at $81.75, well above its 200‑day moving average of $44.34, signaling a strong intermediate‑term uptrend. A 2.9% gain over the last month and an RSI of 55.36 indicate positive momentum without signs of extreme overbought conditions. Technically, the setup appears constructive, with price action supporting a bullish bias as long as it remains above key moving averages.

Price far above the 200‑day moving average ($81.75 vs. $44.34) points to a strong, established uptrend and favorable longer‑term momentum.
RSI at 55.36 sits in neutral‑to‑positive territory, suggesting the stock is neither overbought nor oversold and that recent gains are not yet stretched.
A 2.9% rise over the last month, on top of a large move above the long‑term average, is consistent with ongoing accumulation rather than a fading spike.

Alternative Data Signals

bullish

Hiring activity is robust, with 37 open roles and a 54.2% month‑over‑month increase, a strong signal of expansion in R&D, operations, or commercialization. Social media presence, particularly on LinkedIn, is sizable and growing modestly, suggesting a strengthening professional and industry footprint, even as Twitter/X followers are slightly down. Website traffic is very low, but for a B2B, partner‑driven biopharma like Ionis, hiring and professional‑network traction are more meaningful than raw web visits.

Job openings up 54.2% month over month (to 37 roles) strongly suggest active investment in talent and capacity, typically a forward‑looking, growth‑oriented indicator.
LinkedIn following is large at 100,390 and growing (+1.1% in 90 days), indicating solid professional awareness and employer brand strength in the biotech and pharma ecosystem.
Other social channels show small but positive growth (Instagram +4.8%, Facebook +0.8%, YouTube +1.5%), while a slight Twitter/X decline (-0.1%) is marginal; overall, the social and hiring signals lean expansionary despite low direct web traffic.

Conclusion

neutral

Ionis Pharmaceuticals shows strong technical momentum and encouraging alternative data, particularly in hiring and professional‑network presence, which point toward strategic expansion and confidence in its pipeline or future opportunities. However, the company remains unprofitable, and the negative EPS and distorted P/E ratio underscore that the story is still largely speculative and dependent on future clinical and commercial success. Balancing these factors, the overall stance is neutral, with upside potential driven by growth signals but tempered by ongoing fundamental earnings risk.

Stock price and technical indicators are supportive, but they rest on expectations rather than demonstrated profitability.
Hiring growth and LinkedIn strength are positive forward‑looking signals, yet the lack of current earnings and negative valuation metrics keep the overall outlook balanced rather than clearly bullish.

AI Score

Buy

Alternative8

Fundamental8

Technical6

Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.

Mock Tradesimulated, no real money

You don't hold 0JDI.L in your mock portfolio yet.